Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Šárka Pospíšilová is active.

Publication


Featured researches published by Šárka Pospíšilová.


Leukemia | 2015

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

Panagiotis Baliakas; Anastasia Hadzidimitriou; La. Sutton; Davide Rossi; E. Minga; Neus Villamor; Marta Larrayoz; Jana Kmínková; Andreas Agathangelidis; Zadie Davis; Eugen Tausch; Evangelia Stalika; Barbara Kantorová; Larry Mansouri; Lydia Scarfò; Diego Cortese; Veronika Navrkalová; Mj. Rose-Zerilli; Karin E. Smedby; Gunnar Juliusson; Achilles Anagnostopoulos; A. Makris; Alba Navarro; Julio Delgado; David Oscier; Chrysoula Belessi; Stephan Stilgenbauer; Paolo Ghia; Šárka Pospíšilová; G. Gaidano

Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 (n=3334), SF3B1 (n=2322), TP53 (n=2309), MYD88 (n=1080) and BIRC3 (n=919) genes, mainly at diagnosis (75%) and before treatment (>90%). BIRC3 mutations (2.5%) were associated with unmutated IGHV genes (U-CLL), del(11q) and trisomy 12, whereas MYD88 mutations (2.2%) were exclusively found among M-CLL. NOTCH1, SF3B1 and TP53 exhibited variable frequencies and were mostly enriched within clinically aggressive cases. Interestingly, as the timespan between diagnosis and mutational screening increased, so too did the incidence of SF3B1 mutations; no such increase was observed for NOTCH1 mutations. Regarding the clinical impact, NOTCH1 mutations, SF3B1 mutations and TP53 aberrations (deletion/mutation, TP53ab) correlated with shorter time-to-first-treatment (P<0.0001) in 889 treatment-naive Binet stage A cases. In multivariate analysis (n=774), SF3B1 mutations and TP53ab along with del(11q) and U-CLL, but not NOTCH1 mutations, retained independent significance. Importantly, TP53ab and SF3B1 mutations had an adverse impact even in U-CLL. In conclusion, we support the clinical relevance of novel recurrent mutations in CLL, highlighting the adverse impact of SF3B1 and TP53 mutations, even independent of IGHV mutational status, thus underscoring the need for urgent standardization/harmonization of the detection methods.


Stem Cells | 2009

A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells.

Lívia Eiselleová; Kamil Matulka; Vitezslav Kriz; Michaela Kunová; Zuzana Schmidtová; Jakub Neradil; Boris Tichy; Dana Dvorakova; Šárka Pospíšilová; Aleš Hampl; Petr Dvorak

The transcription program that is responsible for the pluripotency of human ESCs (hESCs) is believed to be comaintained by exogenous fibroblast growth factor‐2 (FGF‐2), which activates FGF receptors (FGFRs) and stimulates the mitogen‐activated protein kinase (MAPK) pathway. However, the same pathway is stimulated by insulin receptors, insulin‐like growth factor 1 receptors, and epidermal growth factor receptors. This mechanism is further complicated by intracrine FGF signals. Thus, the molecular mechanisms by which FGF‐2 promotes the undifferentiated growth of hESCs are unclear. Here we show that, in undifferentiated hESCs, exogenous FGF‐2 stimulated the expression of stem cell genes while suppressing cell death and apoptosis genes. Inhibition of autocrine FGF signaling caused upregulation of differentiation‐related genes and downregulation of stem cell genes. Thus, exogenous FGF‐2 reinforced the pluripotency maintenance program of intracrine FGF‐2 signaling. Consistent with this hypothesis, expression of endogenous FGF‐2 decreased during hESC differentiation and FGF‐2 knockdown‐induced hESC differentiation. In addition, FGF‐2 signaling via FGFR2 activated MAPK kinase/extracellular signal‐regulated kinase and AKT kinases, protected hESC from stress‐induced cell death, and increased hESC adhesion and cloning efficiency. This stimulation of self‐renewal, cell survival, and adhesion by exogenous and endogenous FGF‐2 may synergize to maintain the undifferentiated growth of hESCs. STEM CELLS 2009;27:1847–1857


Leukemia | 2012

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

Šárka Pospíšilová; David Gonzalez; Jitka Malčíková; Martin Trbušek; Davide Rossi; Arnon P. Kater; Florence Cymbalista; Barbara Eichhorst; Michael Hallek; Hartmut Döhner; Peter Hillmen; M. H. J. Van Oers; John G. Gribben; Paolo Ghia; Emili Montserrat; Stephan Stilgenbauer; Thorsten Zenz

Recent evidence suggests that – in addition to 17p deletion – TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ∼5% of untreated CLL patients with treatment indication have a TP53 mutation in the absence of 17p deletion. These patients have a poor response and reduced progression-free survival and overall survival with standard treatment approaches. These data suggest that TP53 mutation testing warrants integration into current diagnostic work up of patients with CLL. There are a number of assays to detect TP53 mutations, which have respective advantages and shortcomings. Direct Sanger sequencing of exons 4–9 can be recommended as a suitable test to identify TP53 mutations for centers with limited experience with alternative screening methods. Recommendations are provided on standard operating procedures, quality control, reporting and interpretation. Patients with treatment indications should be investigated for TP53 mutations in addition to the work-up recommended by the International workshop on CLL guidelines. Patients with TP53 mutation may be considered for allogeneic stem cell transplantation in first remission. Alemtuzumab-based regimens can yield a substantial proportion of complete responses, although of short duration. Ideally, patients should be treated within clinical trials exploring new therapeutic agents.


Biochemical and Biophysical Research Communications | 2009

MicroRNA isolation and stability in stored RNA samples

Marek Mráz; Karla Malinová; Jiří Mayer; Šárka Pospíšilová

MicroRNAs (miRNAs) are small RNA molecules, which act as post-transcriptional regulators of a gene expression, with important functions within the cell physiology. Whilst many authors have focused on the study of miRNA expression in physiological and pathological processes, various technical variables related to miRNA isolation have simultaneously emerged and the stability of the stored miRNA samples has been questioned. A robust method for RNA isolation is essential for reproducible results and miRNAs instability in the stored samples would make for an alarming situation for most expression studies. Here these issues are discussed and we investigate the stability of miRNAs isolated from clinical samples of B lymphocytes (chronic lymphocytic leukemia) by the most commonly utilized method based on a Trizol/TRI-Reagent solution (RNAs stored at -80 degrees C). To assess the stability of miRNAs, a Real Time-PCR analysis was performed for a panel of 29 miRNAs from a freshly isolated RNA sample and after 14 days storage at -80 degrees C. Furthermore, a Real Time-PCR analysis was repeatedly performed for a stored RNA sample over a period of approximately 10 months. We observed high stability of isolated miRNAs and respective cDNAs. The reproducibility and efficiency of the Trizol/TRI-Reagent isolation method was also tested and compared to the mirVana Isolation kit (Ambion) and RNeasy kit (Qiagen). In conclusion, Trizol/TRI-Reagent based isolation is a robust reproducible method, and obtained miRNA samples do not show any tendency to degradation when properly stored and handled.


Leukemia | 2009

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities.

Marek Mráz; Karla Malinová; Jana Kotašková; Šárka Pavlová; Boris Tichý; Jitka Malčíková; Kateřina Staňo Kozubík; Jana Šmardová; Yvona Brychtová; Michael Doubek; Martin Trbušek; Jiří Mayer; Šárka Pospíšilová

Without abstract Without abstract Without abstract Without abstract Without abstract Without abstract Without abstract Without abstract Without abstract Without abstract


Nature Methods | 2014

Towards error-free profiling of immune repertoires

Mikhail Shugay; Olga V. Britanova; Ekaterina M. Merzlyak; Maria A. Turchaninova; Ilgar Z. Mamedov; Timur R Tuganbaev; Dmitriy A. Bolotin; Dmitry B. Staroverov; Ekaterina V. Putintseva; Karla Plevová; Carsten Linnemann; Dmitriy Shagin; Šárka Pospíšilová; Sergey Lukyanov; Ton N. M. Schumacher; Dmitriy M. Chudakov

Deep profiling of antibody and T cell–receptor repertoires by means of high-throughput sequencing has become an attractive approach for adaptive immunity studies, but its power is substantially compromised by the accumulation of PCR and sequencing errors. Here we report MIGEC (molecular identifier groups–based error correction), a strategy for high-throughput sequencing data analysis. MIGEC allows for nearly absolute error correction while fully preserving the natural diversity of complex immune repertoires.


Blood | 2009

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

Jitka Malčíková; Jana Šmardová; Ludmila Rocnova; Boris Tichy; Petr Kuglík; Vladimíra Vranová; Sona Cejkova; Miluše Svitáková; Hana Skuhrová Francová; Yvona Brychtová; Michael Doubek; Martin Brejcha; Martin Klabusay; Jiri Mayer; Šárka Pospíšilová; Martin Trbušek

Deletion of TP53 gene, under routine assessment by fluorescence in situ hybridization analysis, connects with the worst prognosis in chronic lymphocytic leukemia (CLL). The presence of isolated TP53 mutation (without deletion) is associated with reduced survival in CLL patients. It is unclear how these abnormalities are selected and what their mutual proportion is. We used methodologies with similar sensitivity for the detection of deletions (interphase fluorescence in situ hybridization) and mutations (yeast functional analysis) and analyzed a large consecutive series of 400 CLL patients; a subset of p53-wild-type cases (n = 132) was screened repeatedly during disease course. The most common type of TP53 inactivation, ie, mutation accompanied by deletion of the remaining allele, occurred in 42 patients (10.5%). Among additional defects, the frequency of the isolated TP53 mutation (n = 20; 5%) and the combination of 2 or more mutations on separate alleles (n = 5; 1.3%) greatly exceeded the sole deletion (n = 3; 0.8%). Twelve patients manifested defects during repeated investigation; in all circumstances the defects involved mutation and occurred after therapy. Monoallelic defects had a negative impact on survival and impaired in vitro response to fludarabine. Mutation analysis of the TP53 should be performed before each treatment initiation because novel defects may be selected by previous therapies.


Leukemia & Lymphoma | 2009

MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes

Marek Mráz; Šárka Pospíšilová; Karla Malinová; Ivo Šlapák; Jiri Mayer

MicroRNAs (miRNAs) are short, non-coding RNAs, which function as evolutionary conserved regulators of a gene expression. They have essential roles in development, cell differentiation, proliferation, apoptosis and chromosome structure. MiRNAs constitute about 3–5% of predicted genes in the human genome (i.e. about 1000); and 20–30% of the protein-coding genes are estimated to be regulated by the miRNAs. The primary evidence that miRNAs possibly act as a novel class of oncogenes/tumor-suppressors comes from the discovery of the miR-15a and miR-16-1 in 13q14 region deleted in chronic lymphocytic leukemia (CLL). Moreover, miRNA signatures have been used to classify tumor types. There have recently been several reports on the miRNAs role in CLL pathogenesis and disease subtypes (according to IgVH mutation status). In this report, we will review the published observations and present our miRNA profiling data in aggressive CLL with TP53 abnormalities (deletion and/or mutation of p53 gene). We have identified a deregulated miRNA expression pattern (down regulation of miR-34a, miR-29 and miR-17-5p) in these samples, compared to cells with wild-type TP53. It has previously been shown that miR-34a is directly regulated by p53 and targets BCL-2, miR-29c regulates the MCL-1 and TCL-1 proto-oncogenes and the miR-17-5p targets important cell cycle regulatory molecules. Consequently, these three miRNAs could potentially play important roles in the pathogenesis of aggressive CLL.


Leukemia | 2010

TP53 mutation profile in Chronic Lymphocytic Leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations

Thorsten Zenz; D. Vollmer; Martin Trbušek; Jana Šmardová; Axel Benner; Thierry Soussi; H. Helfrich; M. Heuberger; P. Hoth; M. Fuge; Tina Denzel; S. Häbe; Jitka Malčíková; Petr Kuglík; Sim Truong; Nancy Patten; Lin Wu; David Oscier; Rachel E. Ibbotson; Anne Gardiner; Ian Tracy; Ke Lin; Andrew R. Pettitt; Šárka Pospíšilová; Jiří Mayer; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer

The TP53 mutation profile in chronic lymphocytic leukemia (CLL) and the correlation of TP53 mutations with allele status or associated molecular genetics are currently unknown. We performed a large mutation analysis of TP53 at four centers and characterized the pattern of TP53 mutations in CLL. We report on 268 mutations in 254 patients with CLL. Missense mutations appeared in 74% of cases compared with deletions and insertions (20%), nonsense (4%) and splice site (2%) mutations. The majority (243 of 268) of mutations were located in the DNA-binding domain. Transitions were found in 131 of 268 mutations, with only 41 occurring at methylated CpG sites (15%), suggesting that transitions at CpGs are uncommon. The codons most frequently mutated were at positions 175, 179, 248 and 273; in addition, we detected a common 2-nt deletion in the codon 209. Most mutations (199 of 259) were accompanied by deletion of the other allele (17p–). Interestingly, trisomy 12 (without 17p–) was only found in one of 60 cases with TP53 mutation (without 17p–) compared with 60 of 16 in the cohort without mutation (P=0.006). The mutational profile was not different in the cohorts with and without previous therapy, suggesting that the mechanism underlying the development of mutations may be similar, independent of treatment.


Blood | 2011

MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia

Karin Vargova; Nikola Curik; Pavel Burda; Petra Bašová; Vojtěch Kulvait; Vit Pospisil; Filipp Savvulidi; Juraj Kokavec; Emanuel Necas; Adela Berkova; Petra Obrtlikova; Josef Karban; Marek Mráz; Šárka Pospíšilová; Jiří Mayer; Marek Trněný; Jiří Zavadil; Tomas Stopka

Elevated levels of microRNA miR-155 represent a candidate pathogenic factor in chronic B-lymphocytic leukemia (B-CLL). In this study, we present evidence that MYB (v-myb myeloblastosis viral oncogene homolog) is overexpressed in a subset of B-CLL patients. MYB physically associates with the promoter of miR-155 host gene (MIR155HG, also known as BIC, B-cell integration cluster) and stimulates its transcription. This coincides with the hypermethylated histone H3K4 residue and spread hyperacetylation of H3K9 at MIR155HG promoter. Our data provide evidence of oncogenic activities of MYB in B-CLL that include its stimulatory role in MIR155HG transcription.

Collaboration


Dive into the Šárka Pospíšilová's collaboration.

Top Co-Authors

Avatar

Michael Doubek

Central European Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Karla Plevová

Central European Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Jitka Malčíková

Central European Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Trbušek

Central European Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Marek Mráz

Central European Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Boris Tichý

Central European Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Šárka Pavlová

Central European Institute of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge